Methamphetamine, commonly referred to as meth, crystal, or ice, is a potent stimulant with a high propensity for addiction.
It is estimated that a staggering 7.4 million individuals worldwide grapple with dependence or addiction to this substance. Sufferers are exposed to a multitude of grave health hazards, including manifestations like paranoia, suicidal ideation, cardiac complications, cerebrovascular incidents, accidental injuries, and an elevated likelihood of premature mortality.
However, a significant void exists in therapeutic interventions, as no pharmaceutical agents are currently sanctioned globally for the treatment of meth dependence.
Promising findings have now emerged from a readily accessible, cost-effective, and safe medication historically employed in the management of depression. Our investigation into mirtazapine, recently published in JAMA Psychiatry, indicates that individuals receiving this medication exhibit a reduction in their methamphetamine consumption.
Limited Treatment Avenues
Australia contends with one of the highest per capita rates of methamphetamine dependence globally.
Given the absence of approved pharmacological treatments for meth dependence on a worldwide scale, the available intervention strategies are exceedingly limited.
Presently, therapeutic options encompass behavioral interventions, detoxification (withdrawal management), and extended residential rehabilitation programs. Nevertheless, accessibility to these services can be challenging, and patient attrition rates are notably high. A substantial proportion of individuals who undergo rehabilitation programs experience relapse.
More advanced therapeutic modalities implemented within community settings, such as contingency management—which involves establishing objectives and providing incentives for their achievement—demonstrate greater efficacy but are not widely disseminated.
Despite the lack of approved medications for methamphetamine use, clinicians occasionally prescribe existing drugs that have shown preliminary success in controlled clinical trials.
Medications prescribed under an “off-label” designation may include stimulant medications (methylphenidate, lisdexamfetamine, modafinil), bupropion (an anti-smoking agent), naltrexone (an opioid antagonist, sometimes in combination with bupropion), and various antidepressant agents.
However, the effectiveness of these substances can be variable, and they may introduce undesirable adverse effects or safety concerns.
The Potential of Mirtazapine
Research conducted in recent years indicates that mirtazapine, an antidepressant, may present a hopeful avenue.
Two distinct studies were undertaken within an outpatient research setting located in San Francisco, California, United States. Both of these trials yielded findings demonstrating that mirtazapine consumption contributed to a reduction in methamphetamine use.
These initial investigations involved a limited cohort of patients (comprising 60 and 120 participants, respectively) who were under close observation in a research clinic. The participants were identified as being at risk of HIV infection, specifically men and transgender women who engage in sexual activity with men. Women and individuals diagnosed with depression were excluded from these studies.
Consequently, our Australian research collective sought to ascertain whether mirtazapine would yield comparable benefits when administered by clinicians in community-based healthcare facilities to a broader and more heterogeneous patient population.
Methodology and Findings
The Tina Trial enrolled a significantly larger and more diverse group of 339 individuals diagnosed with meth dependence across six outpatient clinics in Australia.
At the commencement of the trial, participants reported an average of 22 days of methamphetamine use within the preceding 28-day period.
Participants were randomly allocated, with half receiving mirtazapine (a 30-milligram tablet administered daily) to take home, while the other half received a placebo, for a duration of 12 weeks. Subsequently, researchers meticulously documented the frequency of methamphetamine usage throughout the 12-week intervention period.
Individuals who were administered mirtazapine exhibited a greater reduction in their methamphetamine use compared to those who received the placebo. The average decrease in usage days was seven out of 28 days for the mirtazapine group, in contrast to 4.8 days for the placebo group.
Therefore, the incremental advantage conferred by mirtazapine was modest, amounting to a reduction of 2.2 days of use within the 28-day cycle.
This observed benefit persisted irrespective of participants’ baseline depression status at the study’s inception.
While this reduction may appear modest, it represents a significant stride forward in the absence of any other approved pharmaceutical alternatives.
Our research team posits that mirtazapine exerts a direct influence on methamphetamine dependence, independent of its antidepressant properties.
This suggests that mirtazapine actively engages with neural circuits implicated in reward pathways, potentially rectifying dysfunctions in systems that can be compromised by prolonged methamphetamine exposure.
Our investigation did not reveal any unanticipated safety concerns associated with the utilization of mirtazapine for the management of meth dependence. The most commonly reported side effects included somnolence and weight gain.
Not a Panacea
Mirtazapine does not constitute an immediate “cure” for methamphetamine dependence. However, in the absence of any globally approved medications for methamphetamine use, it represents a crucial initial step towards providing pharmaceutical interventions to mitigate the detrimental consequences of methamphetamine.
Mirtazapine is characterized by its affordability, safety profile, and widespread availability. A considerable number of physicians are already well-acquainted with its therapeutic application for depression.
As a take-home medication, it offers considerable convenience for patients. Consequently, there is no imperative for daily clinic visits or intensive medical supervision.
Furthermore, it is classified as “off-patent,” meaning that inexpensive generic formulations are accessible.
For mirtazapine to be routinely prescribed for meth dependence outside the confines of a clinical trial, regulatory bodies would need to grant approval for this specific indication. This process necessitates robust research evidence, such as that furnished by the Tina Trial.
In the interim, healthcare providers have the option to prescribe mirtazapine “off-label.” Guidelines pertaining to the off-label prescription of medications are accessible through the Royal Australian and New Zealand College of Psychiatrists.
Additional details regarding the Tina Trial can be accessed here.
Should you have any concerns regarding your own or another individual’s consumption of drugs or alcohol, please contact the National Alcohol and Other Drug Hotline at 1800 250 015. This 24/7 hotline offers confidential, complimentary information and support services.
[Editor’s note: For individuals in the United States seeking information and assistance related to drug and substance abuse, please refer to this resource.]
